menu
    • menu
    [{"orgOrder":0,"company":"UCLA","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Funding","leadProduct":"CAR-T therapy","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"UCLA","amount2":0.01,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"","sponsorNew":"UCLA \/ National Institution of Health","highestDevelopmentStatusID":"1","companyTruncated":"UCLA \/ National Institution of Health"},{"orgOrder":0,"company":"UCLA","sponsor":"Trethera","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"TRE-515","moa":"dCK","graph1":"Neurology","graph2":"Phase I","graph3":"UCLA","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"UCLA \/ UCLA","highestDevelopmentStatusID":"6","companyTruncated":"UCLA \/ UCLA"},{"orgOrder":0,"company":"UCLA","sponsor":"CancerVAX","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Antibody","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"UCLA","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"UCLA \/ UCLA","highestDevelopmentStatusID":"2","companyTruncated":"UCLA \/ UCLA"},{"orgOrder":0,"company":"UCLA","sponsor":"Ananda Scientific","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"UCLA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"UCLA \/ UCLA","highestDevelopmentStatusID":"8","companyTruncated":"UCLA \/ UCLA"}]

    Find Clinical Drug Pipeline Developments & Deals by UCLA

    Menu

    UCLA

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            UCLA

                            U.S.A arrow
                            Cosmoprof
                            Not Confirmed

                            UCLA

                            U.S.A arrow
                            Cosmoprof
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cannabidiol

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Recipient : Ananda Scientific

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            ANANDA and UCLA Begin Trial of Nantheia ATL5 for Smoking Cessation

                            Details : Nantheia ATL5 is an investigational drug that combines cannabidiol with ANANDA’s proprietary Liquid Structure delivery technology, being developed for smoking cessation.

                            Brand Name : Nantheia ATL5

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 22, 2024

                            Lead Product(s) : Cannabidiol

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Recipient : Ananda Scientific

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            UCLA

                            U.S.A arrow
                            Cosmoprof
                            Not Confirmed

                            UCLA

                            U.S.A arrow
                            Cosmoprof
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Antibody,CAR T Cell Therapy

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Recipient : CancerVAX

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            CancerVAX Reports Positive Progress on Kids Cancer Immunotherapy Treatment

                            Details : CAR-T cells and bispecific antibodies targeting this protein biomarker. The findings of this work will create and evaluate new promising tools for recruiting and activating the patient’s own immune system to track and destroy Ewing sarcoma tumors.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            June 12, 2023

                            Lead Product(s) : Antibody,CAR T Cell Therapy

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Recipient : CancerVAX

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            UCLA

                            U.S.A arrow
                            Cosmoprof
                            Not Confirmed

                            UCLA

                            U.S.A arrow
                            Cosmoprof
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TRE-515

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Recipient : Trethera

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Trethera and UCLA Publish Data Demonstrating TRE-515 Ability to Control and Improve Multiple Sclerosis Symptom...

                            Details : TRE-515 is a first-in-class clinical stage drug that inhibits deoxycytidine kinase (dCK), the rate-limiting enzyme in the nucleoside salvage pathway, one of two biosynthetic pathways that generate DNA precursors.

                            Brand Name : TRE-515

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 07, 2022

                            Lead Product(s) : TRE-515

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Recipient : Trethera

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            UCLA

                            U.S.A arrow
                            Cosmoprof
                            Not Confirmed

                            UCLA

                            U.S.A arrow
                            Cosmoprof
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CAR-T therapy

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : National Institutes of Health

                            Deal Size : $14.0 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            UCLA Receives Nearly $14 million from NIH to Investigate Gene Therapy to Combat HIV

                            Details : The five-year grant, part of an NIH effort to develop gene-engineering technologies to cure HIV/AIDS, will fund a collaboration among UCLA; CSL-Behring, to investigate and further develop an immunotherapy known as CAR T.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            June 15, 2020

                            Lead Product(s) : CAR-T therapy

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : National Institutes of Health

                            Deal Size : $14.0 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth